BG107607A - Хидрохлоридна сол на 5-[4-[2-(n-метил-n-(2-пиридил)амино)етокси]бензил]тиазолидин-2,4-дион - Google Patents

Хидрохлоридна сол на 5-[4-[2-(n-метил-n-(2-пиридил)амино)етокси]бензил]тиазолидин-2,4-дион Download PDF

Info

Publication number
BG107607A
BG107607A BG107607A BG10760703A BG107607A BG 107607 A BG107607 A BG 107607A BG 107607 A BG107607 A BG 107607A BG 10760703 A BG10760703 A BG 10760703A BG 107607 A BG107607 A BG 107607A
Authority
BG
Bulgaria
Prior art keywords
hydrochloride
accordance
compound
thiazolidine
pyridyl
Prior art date
Application number
BG107607A
Other languages
Bulgarian (bg)
English (en)
Inventor
Andrew Craig
Michael Millan
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG107607A publication Critical patent/BG107607A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG107607A 2000-09-06 2003-02-28 Хидрохлоридна сол на 5-[4-[2-(n-метил-n-(2-пиридил)амино)етокси]бензил]тиазолидин-2,4-дион BG107607A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021865.1A GB0021865D0 (en) 2000-09-06 2000-09-06 Novel pharmaceutical
PCT/GB2001/003991 WO2002020519A1 (en) 2000-09-06 2001-09-05 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (1)

Publication Number Publication Date
BG107607A true BG107607A (bg) 2003-12-31

Family

ID=9898953

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107607A BG107607A (bg) 2000-09-06 2003-02-28 Хидрохлоридна сол на 5-[4-[2-(n-метил-n-(2-пиридил)амино)етокси]бензил]тиазолидин-2,4-дион

Country Status (35)

Country Link
US (3) US20040034066A1 (es)
EP (1) EP1315723B1 (es)
JP (1) JP2004508369A (es)
KR (1) KR100770513B1 (es)
CN (1) CN100558717C (es)
AP (1) AP1715A (es)
AT (1) ATE300538T1 (es)
AU (2) AU2001284284B2 (es)
BG (1) BG107607A (es)
BR (1) BR0113713A (es)
CA (1) CA2421213A1 (es)
CY (1) CY1105252T1 (es)
CZ (1) CZ302125B6 (es)
DE (1) DE60112310T2 (es)
DK (1) DK1315723T3 (es)
DZ (1) DZ3475A1 (es)
EA (1) EA004296B1 (es)
EC (1) ECSP034505A (es)
ES (1) ES2244647T3 (es)
GB (1) GB0021865D0 (es)
HK (1) HK1057749A1 (es)
HU (1) HUP0300938A3 (es)
IL (2) IL154724A0 (es)
MA (1) MA25908A1 (es)
MX (1) MXPA03001956A (es)
NO (1) NO324020B1 (es)
NZ (1) NZ524548A (es)
OA (1) OA12375A (es)
PL (1) PL360578A1 (es)
PT (1) PT1315723E (es)
SI (1) SI1315723T1 (es)
SK (1) SK2632003A3 (es)
UA (1) UA74003C2 (es)
WO (1) WO2002020519A1 (es)
ZA (1) ZA200301809B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
DE102005034406A1 (de) * 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
JP5063714B2 (ja) * 2010-01-29 2012-10-31 シャープ株式会社 画像読取装置及び画像形成装置
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
RU2487132C1 (ru) * 2012-07-23 2013-07-10 Общество с ограниченной ответственностью "Метаген" Производные циклических 5-нитропиридин-2-ил-тиоалкенил-4-дитиокарбаматов, обладающие противогрибковой активностью, и их применение

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
ES2175230T3 (es) * 1997-07-17 2002-11-16 Interlemo Holding Sa Sistema conector.
CN1183130C (zh) * 1999-09-24 2005-01-05 中国人民解放军军事医学科学院毒物药物研究所 噻唑烷类衍生物及其医药用途
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Also Published As

Publication number Publication date
ECSP034505A (es) 2003-06-25
AP1715A (en) 2007-02-28
CZ302125B6 (cs) 2010-11-03
HUP0300938A3 (en) 2005-04-28
HK1057749A1 (en) 2004-04-16
KR100770513B1 (ko) 2007-10-25
GB0021865D0 (en) 2000-10-18
DE60112310D1 (de) 2005-09-01
WO2002020519A1 (en) 2002-03-14
NO324020B1 (no) 2007-07-30
US20040034066A1 (en) 2004-02-19
IL154724A0 (en) 2003-10-31
MA25908A1 (fr) 2003-10-01
NO20031020L (no) 2003-05-06
ZA200301809B (en) 2004-04-19
NO20031020D0 (no) 2003-03-05
CY1105252T1 (el) 2010-03-03
CN100558717C (zh) 2009-11-11
DZ3475A1 (fr) 2002-03-14
SI1315723T1 (en) 2005-10-31
EP1315723B1 (en) 2005-07-27
DE60112310T2 (de) 2006-02-09
NZ524548A (en) 2004-10-29
EP1315723A1 (en) 2003-06-04
ATE300538T1 (de) 2005-08-15
US20070191435A1 (en) 2007-08-16
CN1366520A (zh) 2002-08-28
KR20030027118A (ko) 2003-04-03
IL154724A (en) 2009-07-20
CZ2003615A3 (cs) 2003-11-12
JP2004508369A (ja) 2004-03-18
AP2003002758A0 (en) 2003-06-30
OA12375A (en) 2004-03-19
PL360578A1 (en) 2004-09-06
HUP0300938A2 (hu) 2003-11-28
US20050282867A1 (en) 2005-12-22
MXPA03001956A (es) 2003-06-24
EA200300345A1 (ru) 2003-08-28
SK2632003A3 (en) 2003-12-02
ES2244647T3 (es) 2005-12-16
PT1315723E (pt) 2005-11-30
UA74003C2 (en) 2005-10-17
AU2001284284B2 (en) 2005-08-04
DK1315723T3 (da) 2005-10-24
EA004296B1 (ru) 2004-02-26
AU8428401A (en) 2002-03-22
CA2421213A1 (en) 2002-03-14
BR0113713A (pt) 2004-07-06

Similar Documents

Publication Publication Date Title
BG107607A (bg) Хидрохлоридна сол на 5-[4-[2-(n-метил-n-(2-пиридил)амино)етокси]бензил]тиазолидин-2,4-дион
KR100840846B1 (ko) 5-[4-[2-(ｎ-메틸-ｎ-(2-피리딜)아미노)에톡시]벤질]티아졸리딘-2,4-디온 메실레이트염
KR100755173B1 (ko) 티아졸리딘디온 유도체의 타르트레이트 염
KR100769007B1 (ko) 티아졸리딘디온 유도체 및 항당뇨제로서의 그의 용도
KR100755174B1 (ko) 티아졸리딘디온 유도체의 타르타르산염
JP2005515987A (ja) ロジグリタゾンエディシレート抗糖尿病剤としてのその使用
KR20030007918A (ko) 당뇨병 치료용 티아졸리딘디온 염
JP2004508370A (ja) チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
BG107605A (bg) Тартаратни соли на тиазолидиндионово производно
KR100754701B1 (ko) 티아졸리딘디온 유도체의 타르타르산염
KR100822135B1 (ko) 티아졸리딘디온 유도체 및 항당뇨제로서의 그의 용도
JP2004508368A (ja) チアゾリジノン硝酸塩
KR20040062963A (ko) 5-(4-(2-(ｎ-메틸-ｎ-(2-피리딜)아미노)에톡시)벤질)티아졸리딘-2,4-디온 벤젠술포네이트, 그의 제조 방법, 그의다형체 ⅰ, ⅱ 및 ⅲ, 및 제약상 활성 성분으로서의 그의용도